September 12, 2024 08:52 AM EDTUpdated 09:13 AM
R&D
Pharma

Gilead says twice-year­ly HIV pre­ven­tion shot suc­ceeds in sec­ond piv­otal tri­al

Lei Lei Wu

News Reporter

Gilead an­nounced that its twice-a-year HIV in­jec­tion pre­vent­ed all but two cas­es of HIV among 2,180 par­tic­i­pants in a Phase 3 study as it pre­pares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times